Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
Nature Genetics
|
June 14, 2005
Use of human tissue to assess the oncogenic activity of melanoma-associated mutations
Yakov Chudnovsky, Amy E Adams, Paul B Robbins, et al.
Diagnostic Pathology
|
October 9, 2016
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
Marlon C Rebelatto, Anita Midha, Amita Mistry, et al.
Liver Cancer
|
July 9, 2021
Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial
Masatoshi Kudo, Kenta Motomura, Yoshiyuki Wada, et al.
Plos One
|
August 4, 2017
Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors
Kathryn C Arbour, Jarushka Naidoo, Keith E Steele, et al.
Journal for Immunotherapy of Cancer
|
November 29, 2016
Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations
Kevin K Dobbin, Alessandra Cesano, John Alvarez, et al.
Journal for Immunotherapy of Cancer
|
November 30, 2016
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation
Giuseppe V Masucci, Alessandra Cesano, Rachael Hawtin, et al.
Cancer Discovery
|
February 22, 2024
Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma
Toni K Choueiri, Amber C Donahue, David A Braun, et al.
The Lancet. Oncology
|
December 13, 2021
HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study
Vivek Naranbhai, Mathias Viard, Michael Dean, et al.
The Lancet. Oncology
|
March 14, 2018
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
Toni K Choueiri, James Larkin, Mototsugu Oya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2021
Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial
Mehmet A Bilen, Brian I Rini, Martin H Voss, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
Nature Genetics
|
June 14, 2005
Use of human tissue to assess the oncogenic activity of melanoma-associated mutations
Yakov Chudnovsky, Amy E Adams, Paul B Robbins, et al.
Diagnostic Pathology
|
October 9, 2016
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma
Marlon C Rebelatto, Anita Midha, Amita Mistry, et al.
Liver Cancer
|
July 9, 2021
Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial
Masatoshi Kudo, Kenta Motomura, Yoshiyuki Wada, et al.
Plos One
|
August 4, 2017
Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors
Kathryn C Arbour, Jarushka Naidoo, Keith E Steele, et al.
Journal for Immunotherapy of Cancer
|
November 29, 2016
Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations
Kevin K Dobbin, Alessandra Cesano, John Alvarez, et al.
Journal for Immunotherapy of Cancer
|
November 30, 2016
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation
Giuseppe V Masucci, Alessandra Cesano, Rachael Hawtin, et al.
Cancer Discovery
|
February 22, 2024
Integrative Analyses of Tumor and Peripheral Biomarkers in the Treatment of Advanced Renal Cell Carcinoma
Toni K Choueiri, Amber C Donahue, David A Braun, et al.
The Lancet. Oncology
|
December 13, 2021
HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study
Vivek Naranbhai, Mathias Viard, Michael Dean, et al.
The Lancet. Oncology
|
March 14, 2018
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
Toni K Choueiri, James Larkin, Mototsugu Oya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2021
Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial
Mehmet A Bilen, Brian I Rini, Martin H Voss, et al.
Page
of 2